Top Page
Beauty Health
(NASDAQ:SKIN)
Beauty Health (SKIN) vs. SPDR S&P 500 ETF (SPY)
Beauty Health Business Overview & Revenue Model
Beauty Health Earnings Call Summary
Beauty Health Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 310.06M | 334.29M | 397.99M | 365.88M | 260.09M | 119.09M |
| Gross Profit | 190.69M | 182.30M | 155.11M | 248.78M | 178.54M | 67.20M |
| EBITDA | 20.71M | 10.34M | -53.56M | 80.75M | -22.00M | -2.81M |
| Net Income | -19.00M | -29.10M | -100.12M | 44.22M | -375.11M | -29.18M |
Balance Sheet | ||||||
| Total Assets | 507.56M | 685.68M | 929.11M | 1.01B | 1.22B | 222.84M |
| Cash, Cash Equivalents and Short-Term Investments | 212.00M | 370.06M | 523.02M | 568.20M | 901.89M | 9.49M |
| Total Debt | 376.73M | 568.16M | 752.29M | 751.79M | 746.41M | 216.54M |
| Total Liabilities | 433.56M | 633.88M | 869.72M | 837.43M | 916.51M | 252.79M |
| Stockholders Equity | 74.00M | 51.80M | 59.39M | 171.48M | 302.30M | -29.96M |
Cash Flow | ||||||
| Free Cash Flow | 36.48M | 9.34M | 8.70M | -123.99M | -43.98M | -16.25M |
| Operating Cash Flow | 39.43M | 16.13M | 21.75M | -106.60M | -28.36M | -12.44M |
| Investing Cash Flow | -5.65M | -6.79M | -31.51M | -18.87M | -37.73M | -3.82M |
| Financing Cash Flow | -174.59M | -158.34M | -37.45M | -205.24M | 959.03M | 18.27M |
Beauty Health Technical Analysis
Beauty Health Risk Analysis
Beauty Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $523.69M | 5.28 | 13.68% | 2.22% | -11.79% | ― | |
65 Neutral | $207.63M | 18.69 | 10.98% | ― | -5.04% | -22.01% | |
63 Neutral | $892.11M | 14.18 | 4.12% | 3.13% | -2.92% | -43.06% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | $231.18M | 42.66 | 34.76% | ― | 65.67% | ― | |
48 Neutral | $465.87M | ― | -52.84% | ― | -5.64% | -577.74% | |
43 Neutral | $175.02M | -4.90 | -26.54% | ― | -15.33% | 75.52% |
Beauty Health Corporate Events
The Beauty Health Company, a medtech meets beauty enterprise, is renowned for its flagship brand Hydrafacial, offering innovative skin health experiences through hydradermabrasion, nanoneedling, and microneedling technologies.
On October 30, 2025, The Beauty Health Company appointed Dr. Philippe Schaison to its Board of Directors, recognizing his extensive experience in scaling global beauty and aesthetics businesses. Dr. Schaison, who currently serves as CEO of Soltégo, Inc., brings over 20 years of leadership in the aesthetics, biotech, and consumer health industries. His appointment is expected to enhance the company’s strategic direction and accelerate growth, particularly for its Hydrafacial brand.
The most recent analyst rating on (SKIN) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Beauty Health stock, see the SKIN Stock Forecast page.
On October 1, 2025, Pedro Malha will assume the role of President and CEO of The Beauty Health Company, succeeding Marla Beck, who will transition to an advisory role. Malha’s extensive experience in the healthcare and medical device sectors positions him to lead the company into its next growth phase, building on Beck’s efforts to enhance innovation and operational efficiency.
The most recent analyst rating on (SKIN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beauty Health stock, see the SKIN Stock Forecast page.
On September 4, 2025, The Beauty Health Company, along with its domestic and foreign subsidiaries, entered into a Supplemental Indenture with U.S. Bank Trust Company to modify an existing indenture related to its 7.95% Convertible Senior Notes due 2028. This modification includes securing the notes with a first-priority guarantee by new foreign subsidiaries and addressing certain ambiguities in the original indenture, potentially strengthening the company’s financial structure and enhancing investor confidence.
The most recent analyst rating on (SKIN) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Beauty Health stock, see the SKIN Stock Forecast page.
The Beauty Health Company’s recent earnings call showcased a strong financial performance, marked by significant improvements in revenue, adjusted EBITDA, and gross margins. The company celebrated successful product launches and strategic debt restructuring, although it acknowledged challenges such as declining device revenue, regional revenue declines, and increased churn. The macroeconomic environment and seasonal factors are expected to impact the upcoming quarter.
The restrictive covenants embedded within the 2028 Notes of Beauty Health Company could significantly constrain its operational flexibility. These covenants limit the company’s ability to engage in debt financing, asset transactions, and various strategic initiatives, including mergers and acquisitions. Such restrictions may hinder the company’s capacity to adapt to industry changes or pursue growth opportunities. Additionally, non-compliance with these covenants could trigger a default event, posing a substantial risk to the company’s financial stability.
The Beauty Health Company, operating in the medtech and beauty sector, specializes in skin health experiences through its flagship brand Hydrafacial, among others. In its second quarter of 2025, BeautyHealth reported a strong financial performance, surpassing revenue and adjusted EBITDA expectations, and subsequently raised its full-year guidance. The company highlighted the success of its HydraFillic with Pep9™ Booster launch and noted significant improvements in gross margins, driven by a shift towards consumable sales. Key financial metrics revealed a decrease in net sales to $78.2 million, a 13.7% drop from the previous year, attributed to lower delivery systems sales. However, the gross margin improved significantly to 62.8% from 45.2%, and net income rose to $19.7 million from $0.2 million. Adjusted EBITDA also saw a notable increase to $13.9 million from a negative $5.2 million, reflecting effective cost management and strategic shifts. Looking ahead, BeautyHealth remains optimistic about its growth trajectory, underpinned by a robust recurring revenue model and ongoing innovation efforts, despite macroeconomic challenges.